Incyte touts mid-stage data for new JAK inhibitor but stops short of selecting PhIII dose
Incyte is rolling out more mid-stage data for its next-gen oral JAK inhibitor, this time in an indication where it’s recently scored an approval with another drug.
Over the weekend at the 2023 American Academy of Dermatology Annual Meeting, the company spelled out results from a Phase IIb trial of povorcitinib among patients with extensive nonsegmental vitiligo, a condition where people’s skin loses color. In the study, the once-daily pill helped more patients than placebo regain color on their skin, as measured by a score of depigmentation called T-VASI (total Vitiligo Area Scoring Index).
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters